XML 39 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2018
Financial Instruments, Owned, at Fair Value [Abstract]  
Fair Value Measurements
Fair Value Measurements
Financial assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets are immaterial at March 31, 2018.
The table below summarizes the carrying amounts and fair values of the Company’s financial instruments (in thousands):
 
March 31, 2018(3)
 
December 31, 2017(3)
 
Carrying
Value
 
Fair Value
 
Carrying
Value
 
Fair Value
Loans receivable, net(2)  
$
47,012

 
$
47,075

 
$
313,326

 
$
313,242

Marketable debt securities(2)  
18,814

 
18,814

 
18,690

 
18,690

Bank line of credit(2)  
1,092,357

 
1,092,357

 
1,017,076

 
1,017,076

Term loan(2)  
236,878

 
236,878

 
228,288

 
228,288

Senior unsecured notes(1)  
6,398,976

 
6,577,155

 
6,396,451

 
6,737,825

Mortgage debt(2)  
143,524

 
137,704

 
144,486

 
125,984

Other debt(2)  
93,856

 
93,856

 
94,165

 
94,165

Interest-rate swap liabilities(2)  
1,931

 
1,931

 
2,483

 
2,483

Cross currency swap liability(2)  
16,684

 
16,684

 
10,968

 
10,968

_______________________________________
(1)
Level 1: Fair value calculated based on quoted prices in active markets.  
(2)
Level 2: Fair value based on (i) for marketable debt securities, quoted prices for similar or identical instruments in active or inactive markets, respectively, or (ii) for loans receivable, net, mortgage debt, and swaps, calculated utilizing standardized pricing models in which significant inputs or value drivers are observable in active markets. For bank line of credit, term loan and other debt, the carrying values are a reasonable estimate of fair value because the borrowings are primarily based on market interest rates and the Company’s credit rating.
(3)
During the three months ended March 31, 2018 and year ended December 31, 2017, there were no material transfers of financial assets or liabilities within the fair value hierarchy.